| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
Trial terminated |
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
date change Primary completion moved earlier: 2026-09-30 -> 2026-03-17 |
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
date change Completion moved earlier: 2027-03-31 -> 2026-03-17 |
| 2026-05-30 | NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… |
Trial sites expanded: 174 -> 181 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07639528 Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted… | Phase 2 | Not Yet Recruiting |
| 2026-05-18 | NCT07594548 Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | Recruiting |
| Phase 2/3 | |||
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy… | Advanced/Metastatic Cancer | Enrolling by Invitation |
| Phase 2 | |||
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or… | Advanced Cholangiocarcinoma | Recruiting |
| NCT02693535 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… | Lymphoma, Non-Hodgkin | Recruiting |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid… | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Active, Not Recruiting |
| NCT07639528 | Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted… | Resectable Intrahepatic Cholangiocarcinoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in… | Pediatric Cancer | Recruiting |
| Phase 1 | |||
| NCT07594548 | Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or… | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Not Yet Recruiting |